A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

INTRODUCTION: The clinical efficacy of trastuzumab and taxanes is at least partly related to their ability to mediate or promote antitumor immune responses. On these grounds, a careful analysis of basal immune profile may be capital to dissect the heterogeneity of clinical responses to these drugs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Muraro, Elena, Martorelli, Debora, Turchet, Elisa, Miolo, Gianmaria, Scalone, Simona, Comaro, Elisa, Talamini, Renato, Mastorci, Katy, Lombardi, Davide, Perin, Tiziana, Carbone, Antonino, Veronesi, Andrea, Crivellari, Diana, Dolcetti, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326559/
https://www.ncbi.nlm.nih.gov/pubmed/22112244
http://dx.doi.org/10.1186/bcr3060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326559/
https://www.ncbi.nlm.nih.gov/pubmed/22112244
http://dx.doi.org/10.1186/bcr3060

Ejemplares similares